Table 5.
Baseline data of cyclosporine-receiving patients.
| Time after Transplantation | 1–5 Years (CsA + MMF) |
>5 Years (CsA + MMF) |
1–5 Years (CsA) |
>5 Years (CsA) |
ANOVA |
|---|---|---|---|---|---|
| Age ± SD (years) (range) |
55.01 ± 14.25 (22–78) |
58.19 ± 13.53 (27–82) |
58.97 ± 13.30 (44–69) |
61.96 ± 13.59 (38–83) |
p = 0.105 |
| CsA dose ± SD (mg) (range) |
204.41 ± 53.82 (120–400) |
183.18 ± 50.14 (60–350) |
233.33 ± 28.87 (200–250) |
164.13 ± 48.55 (70–270) |
p = 0.001 |
| Therapeutic range of the AUC(0–12) exposure (mg/h/L) |
3.05–3.75 | 2.70–2.98 | 3.05–3.75 | 2.70–2.98 | - |
| AUC(0–12) ± SD (mg/h/L) (range) |
3.31 ± 0.94 (1.65–5.65) |
2.97 ± 0.79 (1.46–6.96) |
3.01 ± 0.96 (1.91–3.57) |
2.99 ± 0.70 (1.39–4.27) |
p = 0.087 |
| Therapeutic range of the C0 concentration (µg/L) | 75–150 | 75–150 | 75–150 | 75–150 | - |
| C0 ± SD (µg/L) (range) |
128.55 ± 51.84 (44–258) |
97.90 ± 33.23 (37–240) |
117.33 ± 41.97 (70–150) |
106.54 ± 37.40 (41–187) |
p = 0.000 |
| Number of subjects | 51 | 96 | 3 | 46 | 196 |
ANOVA—analysis of variance; CsA—cyclosporine; MMF—mycophenolate mofetil; SD—standard deviation.